|
Joseph, I B; Isaacs, J T (1998) Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst 90:1648-53
|
|
Hartley-Asp, B; Vukanovic, J; Joseph, I B et al. (1997) Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol 158:902-7
|
|
Joseph, I B; Isaacs, J T (1997) Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 57:1054-7
|
|
Joseph, I B; Nelson, J B; Denmeade, S R et al. (1997) Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 3:2507-11
|
|
Joseph, I B; Vukanovic, J; Isaacs, J T (1996) Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 56:3404-8
|
|
Joseph, I B; Isaacs, J T (1996) The antiangiogenic agent linomide inhibits tumor necrosis factor-alpha secretion via inhibition of its synthesis. Prostate 29:183-90
|
|
Vukanovic, J; Isaacs, J T (1995) Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 55:3517-20
|
|
Vukanovic, J; Isaacs, J T (1995) Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 55:1499-504
|
